Having trouble accessing articles? Reset your cache.

House bill seeks to tweak Orphan Drug Act, could pose threat to pathway

A new bill in the U.S. House of Representatives that seeks to limit abuse of the Orphan Drug Act could have the unintended effect of disincentivizing companies from developing therapies for rare diseases, if the proposed amendment of the act is applied more broadly.

The House Committee

Read the full 461 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE